KTE-X19 CAR-T细胞疗法治疗复发或难治性套细胞淋巴瘤
这项多中心2期试验评估了KTE-X19在复发或难治性套细胞淋巴瘤患者中的疗效,所有患者既往均接受过BTK抑制剂治疗。主要疗效分析显示,60例可评估患者中93%达到客观缓解,67%达到完全缓解;中位随访12.3个月时57%仍处于缓解状态。常见≥3级不良事件为血细胞减少(94%)和感染(32%),≥3级细胞因子释放综合征和神经系统事件发生率分别为15%和31%。
要点
- KTE-X19在既往接受BTK抑制剂的复发/难治套细胞淋巴瘤中客观缓解率达93%。
- ≥3级血细胞减少发生率94%,≥3级感染发生率32%。
- ≥3级细胞因子释放综合征和神经系统事件分别为15%和31%,均无致死性。
核心结论
- KTE-X19在多数复发或难治性套细胞淋巴瘤患者中诱导了持久缓解。
- 该疗法可导致严重且危及生命的毒性反应,与其他CAR-T细胞疗法报道一致。
研究设计与样本
- 多中心、2期试验,评估KTE-X19在复发或难治性套细胞淋巴瘤患者中的疗效。
- 患者既往接受过最多五种治疗且疾病复发或难治,所有患者既往均接受过BTK抑制剂治疗。
- 患者接受白细胞分离术和可选桥接治疗,随后进行预处理化疗并单次输注KTE-X19,剂量为2×10^6 CAR-T细胞/千克体重。
- 主要终点为独立影像学审查委员会根据Lugano分类评估的客观缓解率(完全或部分缓解)。
- 共入组74例患者,71例成功制备KTE-X19,68例接受输注;主要疗效分析在60例患者治疗并随访7个月后进行。
主要发现
- 主要疗效分析中,60例患者93%(95%CI 84-98)达到客观缓解,67%(95%CI 53-78)达到完全缓解。
- 意向性治疗分析中,全部74例患者85%达到客观缓解,59%达到完全缓解。
- 中位随访12.3个月(范围7.0-32.3)时,主要疗效分析中60例患者57%仍处于缓解状态。
- 12个月时估计无进展生存率为61%,总生存率为83%。
- 常见≥3级不良事件为血细胞减少(94%的患者)和感染(32%);≥3级细胞因子释放综合征和神经系统事件发生率分别为15%和31%,均无致死性;发生2例5级感染不良事件。
临床怎么用
- 对于既往接受过BTK抑制剂治疗的复发或难治性套细胞淋巴瘤患者,KTE-X19可作为诱导持久缓解的治疗选择。
- 治疗相关严重毒性(血细胞减少、感染、细胞因子释放综合征和神经系统事件)需密切监测和积极管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with relapsed or refractory mantle-cell lymphoma. METHODS: In a multicenter, phase 2 trial, we evaluated KTE-X19 in patients with relapsed or refractory mantle-cell lymphoma. Patients had disease that had relapsed or was refractory after the receipt of up to five previous therapies; all patients had to have received BTK inhibitor therapy previously. Patients underwent leukapheresis and optional bridging therapy, followed by conditioning chemotherapy and a single infusion of KTE-X19 at a dose of 2×106 CAR T cells per kilogram of body weight. The primary end point was the percentage of patients with an objective response (complete or partial response) as assessed by an independent radiologic review committee according to the Lugano classification. Per the protocol, the primary efficacy analysis was to be conducted after 60 patients had been treated and followed for 7 months. RESULTS: A total of 74 patients were enrolled. KTE-X19 was manufactured for 71 patients and administered to 68. The primary efficacy analysis showed that 93% (95% confidence interval [CI], 84 to 98) of the 60 patients in the primary efficacy analysis had an objective response; 67% (95% CI, 53 to 78) had a complete response. In an intention-to-treat analysis involving all 74 patients, 85% had an objective response; 59% had a complete response. At a median follow-up of 12.3 months (range, 7.0 to 32.3), 57% of the 60 patients in the primary efficacy analysis were in remission. At 12 months, the estimated progression-free survival and overall survival were 61% and 83%, respectively. Common adverse events of grade 3 or higher were cytopenias (in 94% of the patients) and infections (in 32%). Grade 3 or higher cytokine release syndrome and neurologic events occurred in 15% and 31% of patients, respectively; none were fatal. Two grade 5 infectious adverse events occurred. CONCLUSIONS: KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma. The therapy led to serious and life-threatening toxic effects that were consistent with those reported with other CAR T-cell therapies. (Funded by Kite, a Gilead company; ZUMA-2 ClinicalTrials.gov number, NCT02601313.).
引用
- Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020. PMID: 32242358. doi:10.1056/NEJMoa1914347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。